Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
复制标题
DOI：
10.3390/ijms22126413
复制
发表时间：
2021-06-15
影响因子：
5.6
通讯作者：
Pagès G
中科院分区：
文献类型：
--
作者：
Montemagno C;Cassim S;De Leiris N;Durivault J;Faraggi M;Pagès G
胰腺导管腺癌（PDAC）占所有胰腺肿瘤的90-95%，是一种高度破坏性的疾病，预后不良。缺乏准确的诊断测试和传统疗法的失败导致了这一轻蔑的问题。在过去的十年中，核医学治疗诊断学的出现为几种实体瘤的诊断和治疗提供了巨大的机会。已经开发了几种专用于PDAC成像或内部矢量化放射治疗的放射性示踪剂，其中一些目前正在临床考虑中。正电子发射断层扫描（PET）或单光子发射计算机断层扫描（SPECT）提供的功能信息确实可以提供额外的诊断价值，从而有助于选择患者进行靶向治疗。此外，β-和α-发射体放射性标记剂的治疗潜力也可以克服对常规治疗的抗性。这篇综述总结了目前的知识有关的核医学领域的最新发展，PDAC患者的管理。
Pancreatic ductal adenocarcinoma (PDAC), accounting for 90–95% of all pancreatic tumors, is a highly devastating disease associated with poor prognosis. The lack of accurate diagnostic tests and failure of conventional therapies contribute to this pejorative issue. Over the last decade, the advent of theranostics in nuclear medicine has opened great opportunities for the diagnosis and treatment of several solid tumors. Several radiotracers dedicated to PDAC imaging or internal vectorized radiotherapy have been developed and some of them are currently under clinical consideration. The functional information provided by Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) could indeed provide an additive diagnostic value and thus help in the selection of patients for targeted therapies. Moreover, the therapeutic potential of β-- and α-emitter-radiolabeled agents could also overcome the resistance to conventional therapies. This review summarizes the current knowledge concerning the recent developments in the nuclear medicine field for the management of PDAC patients.
登录
查看更多内容
影响因子：
12.4
作者：
Chakravarty R;Goel S;Cai W
通讯作者：
Cai W
影响因子：
4.9
作者：
Aghevlian, Sadaf;Cai, Zhongli;Reilly, Raymond M.
通讯作者：
Reilly, Raymond M.
影响因子：
13.8
作者：
Bryant, Kirsten L.;Mancias, Joseph D.;Kimmelman, Alec C.;Der, Channing J.
通讯作者：
Der, Channing J.
EGF受体是KRAS诱导的胰腺肿瘤发生所必需的。
影响因子：
50.3
作者：
Ardito CM;Grüner BM;Takeuchi KK;Lubeseder-Martellato C;Teichmann N;Mazur PK;Delgiorno KE;Carpenter ES;Halbrook CJ;Hall JC;Pal D;Briel T;Herner A;Trajkovic-Arsic M;Sipos B;Liou GY;Storz P;Murray NR;Threadgill DW;Sibilia M;Washington MK;Wilson CL;Schmid RM;Raines EW;Crawford HC;Siveke JT
通讯作者：
Siveke JT
消化癌和临床应用中的神经素途径：概述。
影响因子：
9
作者：
Christou N;Blondy S;David V;Verdier M;Lalloué F;Jauberteau MO;Mathonnet M;Perraud A
通讯作者：
Perraud A